# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Edward W. Brooke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML014-SYN
- Date: 2026-08-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Howard Bellamy, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Survivorship visit on tamoxifen. **S**

## History of present illness

Mr. Brooke returns three months after his last visit, about nine and a half months into tamoxifen and ten months after surgery. He has missed no doses. Hot flashes remain mild; libido is unchanged and he is not troubled by it. He has had no leg swelling or pain, chest pain, breathlessness, or change in vision, and no new lump, skin change, or swelling on either side of the chest or in either armpit, no bone pain, cough, or weight loss. Since his last visit he has begun speaking publicly about breast cancer in men, to encourage men to have a lump or discomfort in the chest checked and to ask their doctors to examine them. He walks most days and feels well. **S**

| Element | Detail |
|---|---|
| Tamoxifen | About nine and a half months; no missed doses |
| Side effects | Mild hot flashes; lower libido, not bothersome |
| Recurrence symptoms | None |
| Function | Independent; walking most days; busy with speaking and writing |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue, fever, or weight loss |
| Endocrine | Positive | Mild hot flashes |
| Cardiovascular | Negative | No chest pain or leg swelling or pain |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No bone pain |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

6 systems reviewed. **S**

## Current medications

- Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/72 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 82 kg; BMI 24.5 kg/m². All vital signs are synthetic.

PHQ-2: 0. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Chest wall | Mastectomy scars healed on both sides; no nodule or skin change |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Abdomen | Soft; liver not enlarged |
| Musculoskeletal | No spinal tenderness |
| Extremities | Arm circumferences equal; no calf swelling or tenderness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Right breast cancer, stage IIA, no evidence of recurrence** (C50.121). No symptoms or signs of recurrence ten months after surgery. Surveillance continues on the CMID and ACS/ASCO schedule. **S**
   - Written survivorship care plan given today: treatment summary, the tamoxifen plan, the surveillance schedule, symptoms to report, and whom to call.
   - History and examination every three to six months to three years, then every six to twelve months to five years, then yearly.
   - No routine imaging, blood tests, or tumor markers unless symptoms arise.
2. **Long-term tamoxifen** (Z79.810). Well tolerated with good adherence. **S**
   - Continue tamoxifen 20 mg daily; at five years, Dr. Cho will discuss whether to extend it.
   - DXA again in eighteen months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and examination of both sides of the chest wall and both axillae | Every 3 to 6 months for 3 years | Completed today | No evidence of recurrence |
| Examination | Lymphedema assessment | Every visit after axillary surgery | Completed today | No arm swelling |
| Medication safety | Venous thromboembolism symptoms on tamoxifen | Every visit on tamoxifen | Completed today | None |
| Medication safety | Hot flashes on tamoxifen | Every visit on tamoxifen | Completed today | Mild |
| Medication safety | Sexual side effects of tamoxifen | Every visit on tamoxifen | Completed today | Lower libido, stable; no treatment wanted |
| Medication safety | Adherence to tamoxifen | Every visit on tamoxifen | Completed today | No missed doses |
| Survey | Distress and depression screen (PHQ-2) | Every visit | Completed today | PHQ-2 score 0 |
| Survey | Fatigue and cognitive concerns | Every visit | Completed today | None |
| Imaging | Bone density (DXA) | Every 2 years on hormone therapy | Up to date | Six months ago; next in eighteen months |
| Imaging | Breast imaging (mammography) | Yearly only for a remaining breast after lumpectomy, or the other breast with a predisposing variant | Not indicated | Both breasts were removed; there is no breast tissue to image |
| Laboratory | Routine blood tests, tumor markers, and CT, bone scan, or PET | Not recommended without symptoms in stage I to III disease | Not indicated | No symptoms suggesting recurrence |
| Self-management | Survivorship care plan and lifestyle counseling | Within a year of treatment; lifestyle every visit | Completed today | Written plan given; at least 150 minutes of activity a week; no tobacco or alcohol |

## Goal progress

- Take tamoxifen every day with side effects managed, aiming to continue for at least five years. Outcome by 2026-08-11: No missed doses by pill count over seven months; mild hot flashes and a mild fall in libido, both manageable; no clot symptoms. **S**
- Complete germline genetic testing with counseling, and give him written information for his relatives. Outcome by 2026-05-12: No pathogenic variant in a multigene panel; family letter given. **S**
- Establish bone health on hormone therapy at his age: DXA, vitamin D of 30 ng/mL or more, and weight-bearing exercise. Outcome by 2026-05-12: Femoral neck T-score -1.2; vitamin D 36 ng/mL after supplementation. **S**
- Give a written survivorship care plan with the surveillance schedule. Outcome by 2026-08-11: Survivorship care plan given at the survivorship visit. **S**

## Guideline basis

- Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020), American Society of Clinical Oncology
- Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016), American Cancer Society and American Society of Clinical Oncology
- Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Annual wellness visit in two months. Survivorship visit in three to six months. Medical oncology every six months. **S**
- Next scheduled visit 2026-10-13: subsequent annual wellness visit. **S**
